Check our new article entitled “Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab” in Rheumatology (Oxford).
Rheumatology key messages:
- Established neuropsychiatric damage at baseline was associated with an increased hazard to develop NPSLE flare.
- Current or previous NPSLE activity at baseline was the strongest determinant of impending NPSLE flare.
- The potential benefits from belimumab treatment in preventing NPSLE flares remain unclear, warranting future survey.
